Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024

LeonaBio, Inc.

2024-Q1 EPS reported -$0.69

Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.
Cash and investments $122.1M as of March 31, 2024, down from $147.4M at year-end 2023.
LIFT-AD Phase 2/3 topline data for fosgonimeton in Alzheimer's expected H2 2024; enrollment complete.
IND submitted for ATH-1105 (ALS); first-in-human study expected to start Q2 2024.
Appointed Javier San Martin, M.D. as Chief Medical Officer in April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

LeonaBio, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 15, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-060452

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.